Evidence map›Paper›PMID 42333535›Full record

ArticleNucleic acids research2026

SNIPSNP: precision design of CRISPR/Cas9 knock-in reagents for variant correction and disease modeling.

Kornel Labun, Oline Rio, Shiva Dahal-Koirala, Anna Zofia Komisarczuk, Eivind Valen, Emma Haapaniemi

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kornel LabunInstitute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, 02-106 Warsaw, Poland.ORCID 0000-0002-1262-2611
Oline RioNorwegian Centre for Molecular Biosciences and Medicine Norway, University of Oslo, Oslo 0349, Norway.
Shiva Dahal-KoiralaNorwegian Centre for Molecular Biosciences and Medicine Norway, University of Oslo, Oslo 0349, Norway.
Anna Zofia KomisarczukNorwegian Centre for Molecular Biosciences and Medicine Norway, University of Oslo, Oslo 0349, Norway.
Eivind ValenComputational Biology Unit, Department of Informatics, University of Bergen, Bergen 5006, Norway.ORCID 0000-0003-1840-6108
Emma HaapaniemiNorwegian Centre for Molecular Biosciences and Medicine Norway, University of Oslo, Oslo 0349, Norway.

Funding

Kreftforeningen 190290Norges Forskningsråd 331912
6 · The paper itself

Abstract

We present SNIPSNP (crisprtools.org/snipsnp), a comprehensive bioinformatics pipeline for designing experiments for CRISPR-induced homology-directed repair (HDR). The tool addresses the critical challenge of Cas9 re-cleavage by simplifying the selection of "blocking" silent variants that are effective at inhibiting RNP binding upon donor-templated editing. SNIPSNP handles complex edits, including indels, and uses multi-objective optimization to balance editing efficiency with biological safety. From user-defined wild-type and desired HDR alleles, the pipeline identifies candidate guides, annotating them with integrated efficiency scores and genome-wide off-target assessments. Uniquely, SNIPSNP evaluates guide binding against the post-edit genome to determine whether the therapeutic variant alone disrupts repeated Cas9 recognition. When necessary, it introduces synonymous blocking variants, prioritizing PAM and seed regions to minimize re-cleavage probability and editing of the wild-type (WT) allele when editing heterozygous variants. All candidate modifications undergo safety profiling and prioritization of known benign variants from dbSNP. We experimentally validated SNIPSNP and benchmarked it on pathogenic inborn error of immunity variants in primary patient T-cells. Across loci, SNIPSNP-designed templates outperform standard "correction-only" strategies, demonstrating enhanced precision editing, and reduced re-cleavage, establishing SNIPSNP as a robust platform for genome editing and disease modeling.

Indexed as

CRISPR-Cas SystemsGene EditingGene Knock-In TechniquesSoftwareAllelesComputational BiologyHumansINDEL MutationRecombinational DNA RepairRNA, Guide, CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID42333535
PMCPMC13355073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.